

Alasdair MacGowan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5611884/publications.pdf>

Version: 2024-02-01

315
papers

12,514
citations

38742

50
h-index

37204

96
g-index

326
all docs

326
docs citations

326
times ranked

12311
citing authors

#	ARTICLE	IF	CITATIONS
1	The global threat of antimicrobial resistance: science for intervention. <i>New Microbes and New Infections</i> , 2015, 6, 22-29.	1.6	811
2	Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 256-265.	3.0	640
3	EUCAST expert rules in antimicrobial susceptibility testing. <i>Clinical Microbiology and Infection</i> , 2013, 19, 141-160.	6.0	527
4	The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. <i>Clinical Microbiology and Infection</i> , 2017, 23, 2-22.	6.0	428
5	A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in <i>Staphylococcus aureus</i> in a UK hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 399-403.	3.0	361
6	European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 145-148.	3.0	323
7	Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2439-2444.	3.9	290
8	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. <i>Clinical Microbiology and Infection</i> , 2012, 18, E37-E45.	6.0	232
9	Antibiotic treatment of Gram-positive bone and joint infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 928-935.	3.0	221
10	European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. <i>Clinical Microbiology and Infection</i> , 2006, 12, 501-503.	6.0	176
11	Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. <i>Drug Resistance Updates</i> , 2011, 14, 107-117.	14.4	175
12	Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 73-77.	3.0	169
13	Establishing MIC breakpoints and the interpretation of <i>in vitro</i> susceptibility tests. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 17-28.	3.0	166
14	Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 1018-1032.	3.0	126
15	Vancomycin-resistant <i>Staphylococcus aureus</i> . <i>Lancet</i> , The, 1998, 351, 602.	13.7	121
16	A Multicenter Study Evaluating the Current Strategies for Isolating <i>Staphylococcus aureus</i> Strains with Reduced Susceptibility to Glycopeptides. <i>Journal of Clinical Microbiology</i> , 2007, 45, 329-332.	3.9	120
17	Teicoplanin therapy for <i>Staphylococcus aureus</i> septicaemia: relationship between pre-dose serum concentrations and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 835-841.	3.0	119
18	The occurrence and seasonal changes in the isolation of <i>Listeria</i> spp. in shop bought food stuffs, human faeces, sewage and soil from urban sources. <i>International Journal of Food Microbiology</i> , 1994, 21, 325-334.	4.7	118

#	ARTICLE	IF	CITATIONS
19	Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from <i>Stenotrophomonas maltophilia</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1460-1464.	3.2	109
20	Genetic basis of tetracycline resistance in clinical isolates of <i>Listeria monocytogenes</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 463-466.	3.2	106
21	Pharmacodynamics, Pharmacokinetics, and Therapeutic Drug Monitoring of Glycopeptides. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 473-477.	2.0	106
22	Clothing in laminar-flow operating theatres. <i>Journal of Hospital Infection</i> , 1996, 32, 1-7.	2.9	104
23	Importance of air quality and related factors in the prevention of infection in orthopaedic implant surgery. <i>Journal of Hospital Infection</i> , 1998, 39, 173-180.	2.9	104
24	The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 290-295.	3.0	101
25	A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. <i>Journal of Antimicrobial Chemotherapy</i> , 1992, 30, 73-87.	3.0	97
26	Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. <i>The Lancet Digital Health</i> , 2019, 1, e335-e343.	12.3	96
27	Letters to the Editor. <i>Journal of Hospital Infection</i> , 1999, 43, 69-70.	2.9	95
28	Continuous Infusion of β -Lactam Antibiotics. <i>Clinical Pharmacokinetics</i> , 1998, 35, 391-402.	3.5	91
29	<i>Listeria monocytogenes</i> and its role in human infection. <i>Journal of Infection</i> , 1988, 17, 7-28.	3.3	85
30	Tigecycline pharmacokinetic/pharmacodynamic update. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, i11-i16.	3.0	80
31	Distribution and expression of beta-lactamase genes among <i>Aeromonas</i> spp. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 171-178.	3.0	75
32	Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 333-340.	3.0	74
33	A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 605-608.	3.0	73
34	Activities of Moxifloxacin against, and Emergence of Resistance in, <i>Streptococcus pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in an In Vitro Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1088-1095.	3.2	72
35	EUCAST Technical Note on tigecycline. <i>Clinical Microbiology and Infection</i> , 2006, 12, 1147-1149.	6.0	72
36	One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies. <i>European Journal of Epidemiology</i> , 2018, 33, 933-946.	5.7	69

#	ARTICLE	IF	CITATIONS
37	Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 713-718.	3.0	67
38	Clinical implications of antimicrobial resistance for therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, ii105-ii114.	3.0	67
39	One-stage or two-stage revision surgery for prosthetic hip joint infection – the INFORM trial: a study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 90.	1.6	66
40	A clinical isolate of <i>Aeromonas sobria</i> with three chromosomally mediated inducible β -lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 271-279.	3.0	63
41	Enzyme kinetics and biochemical analysis of ImiS, the metallo- β -lactamase from <i>Aeromonas sobria</i> 163a. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 37, 423-431.	3.0	61
42	Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate <i>Staphylococcus aureus</i> (GISA) and Heterogeneous GISA Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 4195-4197.	3.2	61
43	Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections?. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1396-1404.	3.0	61
44	A review of the pharmacokinetics and pharmacodynamics of aztreonam. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2704-2712.	3.0	61
45	The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 146-153.	3.0	60
46	A review of the clinical presentation, laboratory features, antimicrobial therapy and outcome of 77 episodes of pneumococcal meningitis occurring in children and adults. <i>Journal of Infection</i> , 1994, 29, 171-182.	3.3	58
47	A systematic review of matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry compared to routine microbiological methods for the time taken to identify microbial organisms from positive blood cultures. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 863-876.	2.9	57
48	The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. <i>Health Technology Assessment</i> , 2016, 20, 1-294.	2.8	56
49	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1183-1193.	3.2	55
50	Typing of <i>Listeria</i> spp. by random amplified polymorphic DNA (RAPD) analysis. <i>Journal of Medical Microbiology</i> , 1993, 38, 322-327.	1.8	54
51	<i>Listeria faecal</i> carriage by renal transplant recipients, haemodialysis patients and patients in general practice: its relation to season, drug therapy, foreign travel, animal exposure and diet. <i>Epidemiology and Infection</i> , 1991, 106, 157-166.	2.1	53
52	Expression of lux Genes in a Clinical Isolate of <i>Streptococcus pneumoniae</i> : Using Bioluminescence To Monitor Gemifloxacin Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 538-542.	3.2	53
53	Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2754-2759.	3.0	53
54	The antibacterial efficacy of levofloxacin and ciprofloxacin against <i>Pseudomonas aeruginosa</i> assessed by combining antibiotic exposure and bacterial susceptibility. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 345-349.	3.0	52

#	ARTICLE	IF	CITATIONS
55	Surveillance of antimicrobial resistance. <i>BMJ: British Medical Journal</i> , 1998, 317, 614-615.	2.3	51
56	Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 291-298.	2.5	51
57	Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2155-2157.	3.0	49
58	Characterization of cefotaxime-resistant urinary <i>Escherichia coli</i> from primary care in South-West England 2017-18. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 65-71.	3.0	49
59	Sequence analysis of two chromosomally mediated inducible β -lactamases from <i>Aeromonas sobria</i> , strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 41-52.	3.0	48
60	The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales. <i>Value in Health</i> , 2001, 4, 370-375.	0.3	48
61	Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 503-509.	3.0	47
62	Expression and detection of hetero-vancomycin resistance in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 675-678.	3.0	47
63	The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 163-170.	3.0	47
64	NDM-1 polymicrobial infections including <i>Vibrio cholerae</i> . <i>Lancet</i> , The, 2012, 380, 1358.	13.7	47
65	Pharmacodynamics of Ceftaroline against <i>Staphylococcus aureus</i> Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2451-2456.	3.2	47
66	Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1039-1043.	6.0	47
67	Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics. <i>Current Opinion in Pharmacology</i> , 2011, 11, 470-476.	3.5	46
68	Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 181-199.	4.1	45
69	The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 560-567.	2.5	45
70	Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 1983, 40, 440-443.	2.2	45
71	In-vitro activity of HMR 3647 against <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i> and β -haemolytic streptococci. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 445-453.	3.0	44
72	Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 574-577.	2.5	44

#	ARTICLE	IF	CITATIONS
73	Evolution of mobile genetic element composition in an epidemic methicillin-resistant <i>Staphylococcus aureus</i> : temporal changes correlated with frequent loss and gain events. <i>BMC Genomics</i> , 2017, 18, 684.	2.8	43
74	Endophthalmitis at the Bristol Eye Hospital: an 11-year review of 47 patients. <i>Journal of Hospital Infection</i> , 1992, 22, 271-278.	2.9	42
75	An HPLC assay for daptomycin in serum. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1462-1463.	3.0	42
76	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1194-1201.	3.2	42
77	Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study. <i>Emergency Medicine Journal</i> , 2021, 38, 543-548.	1.0	42
78	Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 117-122.	3.0	41
79	Salt tolerance of EMRSA-16 and its effect on the sensitivity of screening cultures. <i>Journal of Hospital Infection</i> , 1997, 35, 59-62.	2.9	41
80	Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3441-3443.	3.2	41
81	Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 1990, 25, 837-842.	3.0	40
82	Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 161-169.	3.0	40
83	Risk Factors for Treatment Failure and Mortality among Hospitalised Patients with Complicated Urinary Tract Infection: A Multicentre Retrospective Cohort Study, RESCUING Study Group. <i>Clinical Infectious Diseases</i> , 2018, 68, 29-36.	5.8	40
84	Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 802-805.	3.0	38
85	Role of early intravenous to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two-stage replacement. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2405-2408.	3.0	38
86	Colistin susceptibility testing: time for a review. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1432-1434.	3.0	38
87	Activity of Moxifloxacin, Administered Once a Day, against <i>Streptococcus pneumoniae</i> in an In Vitro Pharmacodynamic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1560-1564.	3.2	38
88	Virulence of <i>Listeria</i> spp.: Course of infection in resistant and susceptible mice. <i>Journal of Medical Microbiology</i> , 1988, 27, 131-140.	1.8	36
89	The use and therapeutic drug monitoring of teicoplanin in the UK. <i>Clinical Microbiology and Infection</i> , 2004, 10, 62-69.	6.0	36
90	Reduced expression of the <i>atl</i> autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate <i>Staphylococcus aureus</i> (hGISA) and GISA strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 944-947.	3.0	36

#	ARTICLE	IF	CITATIONS
91	Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. <i>Eurosurveillance</i> , 2015, 20, .	7.0	36
92	The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra- abdominal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 121-124.	3.0	35
93	Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 271-275.	3.0	35
94	Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and \hat{A} -haemolytic streptococci collected from western European countries in 2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 164-167.	3.0	35
95	Ciprofloxacin resistant <i>Serratia marcescens</i> endocarditis as a complication of non-Hodgkin's lymphoma. <i>Journal of Infection</i> , 1994, 29, 73-76.	3.3	34
96	The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 165-172.	3.0	34
97	Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 2167-2172.	3.2	34
98	Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 111.	4.1	34
99	Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. <i>BMJ Open</i> , 2018, 8, e020251.	1.9	34
100	A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative \hat{I}^2 -lactam, aminoglycoside and fluoroquinolone. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 193-203.	3.0	33
101	Risk factors for mortality among patients with <i>Pseudomonas aeruginosa</i> bacteraemia: a retrospective multicentre study. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105847.	2.5	33
102	Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. <i>Journal of Infection and Chemotherapy</i> , 1996, 2, 197-208.	1.7	32
103	In Vitro Models, In Vivo Models, and Pharmacokinetics: What Can We Learn from In Vitro Models?. <i>Clinical Infectious Diseases</i> , 2001, 33, S214-S220.	5.8	32
104	Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 198.	4.1	32
105	An eight-year survey of the antimicrobial susceptibility patterns of 85,971 bacteria isolated from patients in a district general hospital and the local community. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 543-557.	3.0	31
106	Hospital-acquired <i>Clostridium difficile</i> diarrhoea. <i>Lancet</i> , The, 1997, 349, 1176-1177.	13.7	31
107	Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 98-101.	2.5	31
108	Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop <i>Clostridium difficile</i> -associated diarrhoea. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 537-541.	3.0	30

#	ARTICLE	IF	CITATIONS
109	Elements of design: the knowledge on which we build. <i>Clinical Microbiology and Infection</i> , 2004, 10, 6-11.	6.0	30
110	Eucast Technical Note on daptomycin. <i>Clinical Microbiology and Infection</i> , 2006, 12, 599-601.	6.0	30
111	Antimicrobial resistance surveillance in urinary tract infections in primary care: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2723-2728.	3.0	30
112	Interactions between Methicillin and Vancomycin in Methicillin-Resistant <i>Staphylococcus aureus</i> Strains Displaying Different Phenotypes of Vancomycin Susceptibility. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3068-3071.	3.9	30
113	Use of a clinical <i>Escherichia coli</i> isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 829-832.	3.0	29
114	Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> : the BSAC Respiratory Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 925-930.	3.0	29
115	Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3982-3983.	3.2	29
116	Pharmacodynamics of Telavancin Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 867-873.	3.2	29
117	Improving the Diagnosis and Treatment of Urinary Tract Infection in Young Children in Primary Care: Results from the DUTY Prospective Diagnostic Cohort Study. <i>Annals of Family Medicine</i> , 2016, 14, 325-336.	1.9	29
118	Supplementary report by the Working Party on antibiotic sensitivity testing of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 1103-1105.	3.0	28
119	The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 483-486.	3.0	28
120	BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 535-539.	3.0	28
121	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	3.5	28
122	Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 661-667.	3.0	27
123	Lack of upward creep of glycopeptide MICs for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) isolated in the UK and Ireland 2001-07. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2912-2918.	3.0	27
124	Risk factors and prognosis of complicated urinary tract infections caused by <i>Pseudomonas aeruginosa</i> in hospitalized patients: a retrospective multicenter cohort study. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2571-2581.	2.7	27
125	Maternal listeriosis in pregnancy without fetal or neonatal infection. <i>Journal of Infection</i> , 1991, 22, 53-57.	3.3	26
126	Pharmacodynamics of Minocycline against <i>Staphylococcus aureus</i> in an <i>In Vitro</i> Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4370-4373.	3.2	26

#	ARTICLE	IF	CITATIONS
127	The diagnosis of urinary tract infections in young children (DUTY): protocol for a diagnostic and prospective observational study to derive and validate a clinical algorithm for the diagnosis of UTI in children presenting to primary care with an acute illness. <i>BMC Infectious Diseases</i> , 2012, 12, 158.	2.9	26
128	Factors influencing the clinical outcome of methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 295-301.	2.9	26
129	The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. <i>Neurourology and Urodynamics</i> , 2017, 36, 2109-2116.	1.5	26
130	Typing of <i>Listeria monocytogenes</i> by random amplified polymorphic DNA (RAPD) analysis. <i>International Journal of Food Microbiology</i> , 1995, 27, 245-252.	4.7	24
131	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for <i>Pseudomonas aeruginosa</i> Bloodstream Infection: A Multisite Retrospective Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2270-2280.	5.8	24
132	A 10 year survey of the epidemiology and clinical aspects of listeriosis in a provincial English city. <i>Journal of Infection</i> , 1994, 29, 91-103.	3.3	23
133	Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 1055-1060.	3.0	23
134	Heterogeneous resistance to vancomycin in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 130-131.	3.0	23
135	A reverse-phase HPLC assay for the simultaneous determination of enrofloxacin and ciprofloxacin in pig faeces. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 390-393.	2.5	23
136	Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of <i>Staphylococcus aureus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1401-1406.	3.2	23
137	Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net. <i>Clinical Infectious Diseases</i> , 2018, 67, 1922-1931.	5.8	23
138	Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for <i>Staphylococcus aureus</i> and streptococci of Lancefield Groups A and G. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 761-766.	3.0	22
139	Pharmacodynamics of Gemifloxacin against <i>Streptococcus pneumoniae</i> in an In Vitro Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2916-2921.	3.2	22
140	Cefuroxime resistance in non-beta-lactamase <i>Haemophilus influenzae</i> is linked to mutations in <i>ftsI</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 523-530.	3.0	22
141	Development of a novel assay method for colistin sulphomethate. <i>Clinical Microbiology and Infection</i> , 2005, 11, 243-244.	6.0	22
142	Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 565.	2.0	22
143	Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 1989, 23, 409-415.	3.0	21
144	In-vitro synergy testing of nine antimicrobial combinations against <i>Listeria monocytogenes</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1990, 25, 561-566.	3.0	21

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 499-505.	3.0	21
146	Role of Pharmacokinetics and Pharmacodynamics: Does the Dose Matter?. <i>Clinical Infectious Diseases</i> , 2001, 33, S238-S239.	5.8	21
147	Activity of AZD2563, a Novel Oxazolidinone, against <i>Staphylococcus aureus</i> Strains with Reduced Susceptibility to Vancomycin or Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3651-3652.	3.2	21
148	Resistance determinants in strains of <i>Clostridium difficile</i> from two geographically distinct populations. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 619-621.	2.5	21
149	Pharmacodynamics of minocycline against <i>Acinetobacter baumannii</i> studied in a pharmacokinetic model of infection. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 715-717.	2.5	21
150	Extent, quality and impact of patient and public involvement in antimicrobial drug development research: A systematic review. <i>Health Expectations</i> , 2018, 21, 75-81.	2.6	21
151	A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 739-740.	3.0	20
152	The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 271-281.	3.0	20
153	A comparison of the penetration of cefuroxime and cephmandole into bone, fat and haematoma fluid in patients undergoing total hip replacement. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 99-104.	3.0	20
154	Back to basics in management of <i>Clostridium difficile</i> infections. <i>Lancet</i> , The, 1998, 352, 505-506.	13.7	20
155	Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4234-4239.	3.2	20
156	Breakpoints for extended-spectrum β -lactamase-producing Enterobacteriaceae: pharmacokinetic/pharmacodynamic considerations. <i>Clinical Microbiology and Infection</i> , 2008, 14, 166-168.	6.0	20
157	Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg iv bd irrespective of renal function. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 1051-1054.	3.0	19
158	Assay of low trough serum gentamicin concentrations by fluorescence polarization immunoassay. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 1068-1070.	3.0	19
159	Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 73-78.	3.0	19
160	Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1044-1051.	3.0	19
161	Pharmacodynamics of Razupenem (PZ601) Studied in an In Vitro Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1436-1442.	3.2	19
162	Comparative antibacterial effects of moxifloxacin and levofloxacin on <i>Streptococcus pneumoniae</i> strains with defined mechanisms of resistance: impact of bacterial inoculum. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1130-1138.	3.0	19

#	ARTICLE	IF	CITATIONS
163	Methodological features of clinical pharmacokinetic–pharmacodynamic studies of antibacterials and antifungals: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1374-1389.	3.0	19
164	Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2172-2181.	3.0	19
165	Heterogeneity at the β -lactamase structural gene ampC amongst <i>Citrobacter</i> spp. assessed by polymerase chain reaction analysis: potential for typing at a molecular level. <i>Journal of Medical Microbiology</i> , 1994, 41, 209-214.	1.8	18
166	Detection of glycopeptide resistance in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 357-358.	3.0	18
167	In vitro activity of 21 antimicrobials against vancomycin-resistant <i>Staphylococcus aureus</i> (VRSA) and heteroVRSA (hVRSA). <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 760-761.	3.0	18
168	Antibacterial Effects of Amoxicillin-Clavulanate against <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> Strains for Which MICs Are High, in an In Vitro Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2599-2603.	3.2	18
169	Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 515-521.	3.2	18
170	The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 809-812.	3.0	17
171	For debate. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 829-837.	3.0	17
172	Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin. lesassays@ukneqasaa.win-uk.net . <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 355-361.	3.0	17
173	Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 461-467.	3.0	17
174	Mechanism of Fluoroquinolone Resistance Is an Important Factor in Determining the Antimicrobial Effect of Gemifloxacin against <i>Streptococcus pneumoniae</i> in an In Vitro Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1096-1100.	3.2	17
175	Impact of rapid microbial identification on clinical outcomes in bloodstream infection: the RAPIDO randomized trial. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1347-1354.	6.0	17
176	Listeriosis—the therapeutic options. <i>Journal of Antimicrobial Chemotherapy</i> , 1990, 26, 721-721.	3.0	16
177	Serum monitoring and practicalities of once-daily aminoglycoside dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 349-350.	3.0	16
178	The elution and binding characteristics of rifampicin for three commercially available protein-sealed vascular grafts. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 599-604.	3.0	16
179	An isocratic high performance liquid chromatography (HPLC) assay for moxifloxacin, a new 8-methoxyquinolone. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 278-279.	3.0	16
180	Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 931-943.	3.0	16

#	ARTICLE	IF	CITATIONS
181	Pharmacodynamics of linezolid in a clinical isolate of <i>Streptococcus pneumoniae</i> genetically modified to express lux genes. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 511-513.	3.0	16
182	Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in an <i>In Vitro</i> Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5009-5015.	3.2	16
183	Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 23.	3.8	16
184	An audit of the use of manual handling equipment and their microbiological flora – implications for infection control. <i>Journal of Hospital Infection</i> , 1999, 43, 309-313.	2.9	15
185	In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 557-561.	2.5	15
186	Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5181-5184.	3.2	15
187	Future treatment options for Gram-positive infections – looking ahead. <i>Clinical Microbiology and Infection</i> , 2009, 15, 17-25.	6.0	15
188	Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay. <i>Journal of Infection</i> , 2020, 81, e7-e9.	3.3	15
189	The pharmacokinetics of norfloxacin in the aged. <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 22, 721-727.	3.0	14
190	Relapsed infection due to <i>Listeria monocytogenes</i> confirmed by random amplified polymorphic DNA (RAPD) analysis. <i>Journal of Infection</i> , 1993, 27, 205-207.	3.3	14
191	Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 37, 1-5.	3.0	14
192	External quality assessment of the serum bactericidal test: results of a methodology/interpretation questionnaire. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 277-284.	3.0	14
193	Three cases of meningococcal pneumonia.. <i>Thorax</i> , 1997, 52, 927-929.	5.6	14
194	Surveillance of antimicrobial resistance. <i>Lancet</i> , The, 1998, 352, 1783.	13.7	14
195	Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 327-328.	3.0	14
196	Expression of <i>tcaA</i> and <i>mprF</i> and glycopeptide resistance in clinical glycopeptide-intermediate <i>Staphylococcus aureus</i> (GISA) and heteroGISA strains. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2005, 1726, 326-327.	2.4	14
197	The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β -lactamase-producing Enterobacteriaceae studied in an <i>in vitro</i> model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw480.	3.0	14
198	An <i>in vitro</i> biofilm model of <i>Staphylococcus aureus</i> infection of bone. <i>Letters in Applied Microbiology</i> , 2019, 68, 294-302.	2.2	14

#	ARTICLE	IF	CITATIONS
199	Needlestick injuries among medical students. <i>Journal of Hospital Infection</i> , 1993, 23, 315-317.	2.9	13
200	The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant <i>Staphylococcus aureus</i> explored using an in vitro pharmacokinetic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 727-730.	3.0	13
201	Determination by HPLC of chlortetracycline in pig faeces. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 135-137.	3.0	13
202	Assay of ertapenem in human serum by high-performance liquid chromatography. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 165-167.	2.5	13
203	Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	13
204	Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 90-98.	2.8	13
205	In vitro pharmacodynamics of omadacycline against <i>Escherichia coli</i> and <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 667-670.	3.0	13
206	Limited phylogenetic overlap between fluoroquinolone-resistant <i>Escherichia coli</i> isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3144-3150.	3.0	13
207	The comparative inhibitory and bactericidal activities of meropenem and imipenem against <i>Acinetobacter</i> spp. and <i>Enterobacteriaceae</i> resistant to second generation cephalosporins. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 333-337.	3.0	12
208	Contamination of wounds by direct inoculation in total hip arthroplasty: a prospective clinical study. <i>Journal of Hospital Infection</i> , 1998, 40, 79-80.	2.9	12
209	A reverse-phase, isocratic high-performance liquid chromatography assay for levofloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 434-435.	3.0	12
210	Ofloxacin Photodegradation Products Possess Antimicrobial Activity. <i>Drugs</i> , 1999, 58, 171-172.	10.9	12
211	A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF). <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1041-1042.	3.0	12
212	Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2411-2417.	3.0	12
213	A long history of β -lactams for MRSA. <i>Nature Microbiology</i> , 2019, 4, 1604-1605.	13.3	12
214	Challenges and opportunities for involving patients and the public in acute antimicrobial medicine development research: an interview study. <i>BMJ Open</i> , 2019, 9, e024918.	1.9	12
215	Pathways to optimising antibiotic use in rural China: identifying key determinants in community and clinical settings, a mixed methods study protocol. <i>BMJ Open</i> , 2019, 9, e027819.	1.9	12
216	HPLC assay of cefixime in serum and CSF. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 450-450.	3.0	11

#	ARTICLE	IF	CITATIONS
217	Comparison of E test with conventional agar MICs for quinolones. Journal of Antimicrobial Chemotherapy, 1994, 33, 356-356.	3.0	11
218	A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative β -lactam, aminoglycoside and fluoroquinolone. Journal of Antimicrobial Chemotherapy, 1995, 35, 569-576.	3.0	11
219	Treatment of listeria meningitis. Lancet, The, 1997, 350, 1034.	13.7	11
220	Ampicillin-aminoglycoside interaction studies using <i>Listeria monocytogenes</i> . Journal of Antimicrobial Chemotherapy, 1998, 41, 417-418.	3.0	11
221	Pharmacokinetics of Once-a-Day Netilmicin (4.5 mg/kg) in Neonates. Journal of Chemotherapy, 2001, 13, 270-276.	1.5	11
222	Prevalence of antibiotic resistance in <i>Escherichia coli</i> isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England. Journal of Antimicrobial Chemotherapy, 2015, 70, 2167-2169.	3.0	11
223	Genomic sequences of <i>Streptococcus agalactiae</i> with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance. Journal of Antimicrobial Chemotherapy, 2017, 72, 2704-2707.	3.0	11
224	Why monitor peak vancomycin concentrations?. Lancet, The, 1995, 345, 645-647.	13.7	10
225	Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis. Journal of Antimicrobial Chemotherapy, 2000, 45, 247-250.	3.0	10
226	Viral infections in pregnancy: advice for healthcare workers. Journal of Hospital Infection, 2014, 87, 11-24.	2.9	10
227	Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen. International Journal of Antimicrobial Agents, 2019, 54, 750-756.	2.5	10
228	Tricuspid valve infective endocarditis and pulmonary sepsis due to <i>Erysipelothrix rhusiopathiae</i> successfully treated with high doses of ciprofloxacin but complicated by gynaecomastia. Journal of Infection, 1991, 22, 100-101.	3.3	9
229	Venous allografts prepared from stripped long saphenous vein. Is there a need for antibiotic sterilisation?. European Journal of Vascular and Endovascular Surgery, 1998, 15, 444-448.	1.5	9
230	Epidemiology and resource utilization for patients hospitalized for lower respiratory tract infection. Clinical Microbiology and Infection, 2001, 7, 666-670.	6.0	9
231	EUCAST Technical Note on linezolid. Clinical Microbiology and Infection, 2006, 12, 1243-1245.	6.0	9
232	Occurrence and current frequency of CTX-M-type β -lactamases from a regional hospital in the South West of England. Journal of Antimicrobial Chemotherapy, 2007, 59, 815-816.	3.0	9
233	Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility. Journal of Antimicrobial Chemotherapy, 2010, 65, 183-185.	3.0	9
234	Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING). BMJ Open, 2016, 6, e011500.	1.9	9

#	ARTICLE	IF	CITATIONS
235	The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 51-61.	3.0	8
236	The serum concentrations of desmethyl ofloxacin and ofloxacin N-oxide in seriously ill patients and their possible contributions to the antibacterial activity of ofloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 300-303.	3.0	8
237	The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 701-706.	3.0	8
238	Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. <i>Journal of Infection</i> , 1998, 37, 30-36.	3.3	8
239	A Comparative Study of the Rifampicin Binding and Elution Characteristics for Collagen- and Albumin-sealed Vascular Grafts. <i>European Journal of Vascular and Endovascular Surgery</i> , 1999, 17, 347-350.	1.5	8
240	In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 578-580.	3.0	8
241	Strain-Specific Expression Levels of <i>pbp4</i> Exist in Isolates of Glycopeptide-Intermediate <i>Staphylococcus aureus</i> (GISA) and Heterogeneous GISA. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3598-3599.	3.2	8
242	Frontline antibiotic therapy. <i>Clinical Medicine</i> , 2013, 13, 263-268.	1.9	8
243	Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1692-1693.	6.0	8
244	The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 101-107.	3.0	7
245	Assay of serum teicoplanin concentrations in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarisation fluoroimmunoassay and bioassay. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 425-429.	3.0	6
246	In Vitro Studies on the Impact of Human Serum on the Antibacterial Effect of Faropenem. <i>Journal of Chemotherapy</i> , 2004, 16, 23-29.	1.5	6
247	Genetic analysis of 17 genes in <i>Staphylococcus aureus</i> with reduced susceptibility to vancomycin (VISA) and heteroVISA. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 406-407.	3.0	6
248	Problems of basing patient recruitment for primary care studies on routine laboratory submissions. <i>Journal of Clinical Pathology</i> , 2007, 60, 1290-1293.	2.0	6
249	Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 30-33.	2.5	6
250	In Vitro Activities of Three New Dihydrofolate Reductase Inhibitors against Clinical Isolates of Gram-Positive Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4949-4952.	3.2	6
251	Nappy pad urine samples for investigation and treatment of UTI in young children: the "DUTY"™ prospective diagnostic cohort study. <i>British Journal of General Practice</i> , 2016, 66, e516-e524.	1.4	6
252	Comparison of microbiological diagnosis of urinary tract infection in young children by routine health service laboratories and a research laboratory: Diagnostic cohort study. <i>PLoS ONE</i> , 2017, 12, e0171113.	2.5	6

#	ARTICLE	IF	CITATIONS
253	Finding and engaging patients and the public to work collaboratively on an acute infection microbiology research public panel. <i>Research Involvement and Engagement</i> , 2018, 4, 3.	2.9	6
254	Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3212-3215.	3.0	6
255	Challenges in the bioanalysis of tetracyclines: Epimerisation and chelation with metals. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1134-1135, 121807.	2.3	6
256	Duration of Treatment for <i>Pseudomonas aeruginosa</i> Bacteremia: a Retrospective Study. <i>Infectious Diseases and Therapy</i> , 0, , .	4.0	6
257	Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891. <i>Journal of Antimicrobial Chemotherapy</i> , 1992, 29, 179-185.	3.0	5
258	An evaluation of three new immunoassays for determination of serum gentamicin concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 747-754.	3.0	5
259	Microbiologically proven bacterial infections in AIDS. <i>Postgraduate Medical Journal</i> , 1997, 73, 565-570.	1.8	5
260	Screening for EMRSA-16 in healthcare workers. <i>Journal of Hospital Infection</i> , 1997, 37, 75-77.	2.9	5
261	Pharmacodynamics of Ceftazidime plus the Serine β -Lactamase Inhibitor AM-112 against <i>Escherichia coli</i> Containing TEM-1 and CTX-M-1 β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4482-4484.	3.2	5
262	Determination of avilamycin A and B in pig faeces by solid phase extraction and reverse-phase HPLC assay. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 511-514.	2.5	5
263	A non-fatal case of hantavirus cardiopulmonary syndrome imported into the UK (ex Panama), July 2014. <i>Journal of Clinical Virology</i> , 2015, 67, 52-55.	3.1	5
264	Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1945-1951.	3.0	5
265	Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against <i>Escherichia coli</i> and <i>Streptococcus pneumoniae</i> as an exemplary example. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105809.	2.5	5
266	Clinical diagnosis and treatment of common respiratory tract infections in relation to microbiological profiles in rural health facilities in China: implications for antibiotic stewardship. <i>BMC Family Practice</i> , 2021, 22, 87.	2.9	5
267	Once-a-day carbapenem therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 327-328.	3.0	4
268	The in vitro activity of moxifloxacin against <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> explored using a pharmacodynamic model. <i>Clinical Microbiology and Infection</i> , 1999, 5, 195-200.	6.0	4
269	Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1270-1278.	3.0	4
270	Towards better antimicrobial susceptibility testing: impact of the <i>Journal of Antimicrobial Chemotherapy</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 323-329.	3.0	4

#	ARTICLE	IF	CITATIONS
271	Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1305-1313.	3.0	4
272	1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects. <i>Open Forum Infectious Diseases</i> , 2018, 5, S425-S426.	0.9	4
273	Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 626-632.	2.5	4
274	Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1949-1950.	3.0	4
275	False-positive agglutinations with <i>Listeria monocytogenes</i> using a commercial kit for Lancefield grouping of beta-haemolytic streptococci. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1988, 7, 208-210.	2.9	3
276	Antimicrobial chemotherapy of meningitis due to <i>Listeria monocytogenes</i> in adults. <i>Journal of Infection</i> , 1992, 25, 119-120.	3.3	3
277	ANAEROBIC EXPERIENCE OF FLUOROQUINOLONES AND EPIDEMIOLOGY IN THE UNITED KINGDOM AND EUROPE. <i>Infectious Diseases in Clinical Practice</i> , 1996, 5, S85-S91.	0.3	3
278	Difficulties in the assay of liposomal amikacin (MiKasome) in serum. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 719-721.	3.0	3
279	Choosing the right anticoagulant: a critical choice when assessing pharmacokinetic parameters for tetracyclines obtained from human blood samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3643-3645.	3.0	3
280	The pharmacodynamics of fosfomycin against <i>Staphylococcus aureus</i> studied in an in vitro model of infection. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105985.	2.5	3
281	Risk factors for hospital readmission following complicated urinary tract infection. <i>Scientific Reports</i> , 2021, 11, 6926.	3.3	3
282	Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2005-2010.	2.9	3
283	The pharmacodynamics of minocycline alone and in combination with rifampicin against <i>Staphylococcus aureus</i> studied in an in vitro pharmacokinetic model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1840-1844.	3.0	3
284	In Vitro Activities of Y-688, a New 7-Substituted Fluoroquinolone, against Anaerobic Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 419-424.	3.2	3
285	Exploring the Pharmacokinetics of Phenoxymethylpenicillin (Penicillin-V) in Adults: A Healthy Volunteer Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab573.	0.9	3
286	The activity of cefixime against 715 urinary isolates of Enterobacteriaceae isolated from general practice and out-patients in twenty centres across the British Isles. <i>Journal of Antimicrobial Chemotherapy</i> , 1992, 30, 554-556.	3.0	2
287	Decrease in antibiotic susceptibility or increase in resistance?-- defects of present antimicrobial susceptibility surveillance. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 547-548.	3.0	2
288	Use of Intravenous Co-Trimoxazole to Treat Bacterial Infection: Analysis of 50 Treatment Episodes. <i>Journal of Chemotherapy</i> , 2010, 22, 267-269.	1.5	2

#	ARTICLE	IF	CITATIONS
289	Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 178-179.	2.2	2
290	Cost-effectiveness of rapid laboratory-based mass-spectrometry diagnosis of bloodstream infection: evidence from the RAPIDO randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e044623.	1.9	2
291	When is penicillin monotherapy the antibiotic treatment of choice?. <i>Journal of Antimicrobial Chemotherapy</i> , 1992, 29, 239-243.	3.0	1
292	The management of mycobacterial infection – a UK survey. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 745-747.	3.0	1
293	Control of varicella-zoster infection on renal and other specialist units. <i>Journal of Hospital Infection</i> , 1997, 36, 133-140.	2.9	1
294	A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in <i>Staphylococcus aureus</i> in a UK hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 161-161.	3.0	1
295	Antimicrobial therapy: principles of use. <i>Medicine</i> , 2013, 41, 635-641.	0.4	1
296	Comment on: Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2711-2712.	3.0	1
297	Emulating the MERINO randomised control trial using data from an observational cohort and trial of rapid diagnostic (BSI-FOO). <i>PLoS ONE</i> , 2022, 17, e0268807.	2.5	1
298	Penetration of cefixime into the cerebrospinal fluid of patients with non-inflamed meninges. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 783-784.	3.0	0
299	Trends in original research published from the United Kingdom in the antimicrobial chemotherapy literature, 1980–1994. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 1097-1101.	3.0	0
300	In vitro methods for confirming reduced susceptibility to cefuroxime among <i>Haemophilus influenzae</i> isolates. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997, 16, 328-329.	2.9	0
301	Novel strategies for the use of antibiotics. <i>Current Opinion in Infectious Diseases</i> , 1998, 11, 471-474.	3.1	0
302	Antimicrobial Activity of Moxifloxacin and Levofloxacin Photodegradation Products. <i>Drugs</i> , 1999, 58, 144-145.	10.9	0
303	Clinafloxacin serum concentrations in a patient on continuous veno-venous haemofiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 927-928.	3.0	0
304	Trends in original research published from the United Kingdom in the antimicrobial literature. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 429-430.	3.0	0
305	Tigecycline pharmacokinetic/pharmacodynamic update. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1549-1549.	3.0	0
306	Prospective observational cohort study of patients colonised and infected with Methicillin Resistant <i>S.aureus</i> (MRSA) in a UK teaching hospital. <i>Journal of Infection</i> , 2011, 63, e33.	3.3	0

#	ARTICLE	IF	CITATIONS
307	Reply to "Breakthrough Bacteremia Due to Extended-Spectrum- β -Lactamase-Producing <i>Klebsiella pneumoniae</i> during Combination Therapy with Colistin and Tigecycline" Antimicrobial Agents and Chemotherapy, 2012, 56, 4996-4996.	3.2	0
308	Lack of upward creep of glycopeptide MICs for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) isolated in the UK and Ireland 2001-07--authors' response. Journal of Antimicrobial Chemotherapy, 2013, 68, 1693-1694.	3.0	0
309	Patient and public involvement in infection clinical research. Clinical Microbiology and Infection, 2018, 24, 1121-1122.	6.0	0
310	Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?"authors'™ response. Journal of Antimicrobial Chemotherapy, 2019, 74, 1767-1767.	3.0	0
311	Pharmacodynamics of aztreonam against <i>Escherichia coli</i> and <i>Klebsiella oxytoca</i> : defining pharmacodynamic targets. Journal of Antimicrobial Chemotherapy, 2020, 75, 772-773.	3.0	0
312	Impact of recent EUCAST method changes in an English region. Journal of Antimicrobial Chemotherapy, 2021, 76, 3066.	3.0	0
313	Pharmacokinetics of Lopinavir/Ritonavir in Hospitalized Patients with COVID-19 Not Requiring Critical Care. Microbial Drug Resistance, 2022, , .	2.0	0
314	Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. Clinical Microbiology and Infection, 2022, , .	6.0	0
315	Comment on: Vancomycin in adult prescribing: is it time to move on from trough-based dosing in the UK?. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	0